Akorn Stock Price, News & Analysis (NASDAQ:AKRX)

$32.20 -0.44 (-1.35 %)
(As of 12/13/2017 09:42 AM ET)
Previous Close$32.64
Today's Range$32.09 - $32.66
52-Week Range$17.74 - $34.00
Volume2.54 million shs
Average Volume2.69 million shs
Market Capitalization$4.08 billion
P/E Ratio20.27
Dividend YieldN/A
Beta1.33

About Akorn (NASDAQ:AKRX)

Akorn logoAkorn Inc. (Akorn), together with its subsidiaries, is a specialty generic pharmaceutical company that develops, manufactures and markets generic and branded prescription pharmaceuticals, as well as private-label over-the-counter (OTC) consumer health products and animal health pharmaceuticals. The Company operates through two segments: Prescription Pharmaceuticals and the Consumer Health. The Prescription Pharmaceuticals segment consists of generic and branded prescription pharmaceuticals in a range of dosage forms, including sterile ophthalmics, injectables and inhalants and non-sterile oral liquids, topicals and nasal sprays and otics. The Consumer Health segment consists of branded and private-label OTC products and animal health products dispensed by veterinary professionals. Its branded and private-label OTC products are focused on ophthalmics, including a dry eye treatment TheraTears Therapy for Your Eyes.

Receive AKRX News and Ratings via Email

Sign-up to receive the latest news and ratings for AKRX and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceuticals
Sub-IndustryPharmaceuticals
SectorMedical
SymbolNASDAQ:AKRX
CUSIP00972810
Phone847-279-6100

Debt

Debt-to-Equity Ratio0.92%
Current Ratio4.16%
Quick Ratio3.17%

Price-To-Earnings

Trailing P/E Ratio20.27
Forward P/E Ratio33.89
P/E Growth2.04

Sales & Book Value

Annual Sales$1.12 billion
Price / Sales3.61
Cash Flow$2.93 per share
Price / Cash10.98
Book Value$6.54 per share
Price / Book4.92

Profitability

Trailing EPS$0.99
Net Income$184.24 million
Net Margins7.79%
Return on Equity15.14%
Return on Assets6.51%

Miscellaneous

Employees2,388
Outstanding Shares125,070,000

Akorn (NASDAQ:AKRX) Frequently Asked Questions

What is Akorn's stock symbol?

Akorn trades on the NASDAQ under the ticker symbol "AKRX."

How were Akorn's earnings last quarter?

Akorn, Inc. (NASDAQ:AKRX) issued its quarterly earnings data on Thursday, August, 4th. The company reported $0.58 earnings per share for the quarter, topping analysts' consensus estimates of $0.55 by $0.03. The business had revenue of $280.70 million for the quarter, compared to analyst estimates of $272.99 million. Akorn had a return on equity of 15.14% and a net margin of 7.79%. The business's quarterly revenue was up 27.1% compared to the same quarter last year. View Akorn's Earnings History.

Where is Akorn's stock going? Where will Akorn's stock price be in 2017?

9 equities research analysts have issued 1-year price targets for Akorn's shares. Their predictions range from $24.00 to $40.00. On average, they anticipate Akorn's stock price to reach $31.83 in the next twelve months. View Analyst Ratings for Akorn.

What are Wall Street analysts saying about Akorn stock?

Here are some recent quotes from research analysts about Akorn stock:

  • 1. According to Zacks Investment Research, "Akorn, Inc. manufactures and markets diagnostic and therapeutic pharmaceuticals in specialty areas such as ophthalmology, rheumatology, anesthesia and antidotes, among others. They also market ophthalmic surgical instruments and related products. Customers include physicians, optometrists, wholesalers, group purchasing organizations and other pharmaceutical companies. They also provide contract manufacturing services. " (10/24/2017)
  • 2. Royal Bank of Canada analysts commented, "We now see two major hurdles lifted (i) a much needed reset on 2017 EPS and (ii) greater comfort on new approvals from Decatur. From here, debate will move to whether there is enough new launch revenue to offset erosion and drive growth beyond 2017. Story is de-risked meaningfully but we are still struggling to find growth off lower base. Target down to $21... Leading into 4Q we have been concerned that Street numbers for 2017 were meaningfully too high and that new approvals were not coming from the Decatur facility. First time 2017 guidance of $1.53 to $1.72 should re-set the Street's $2.17, lowering the bar for this year, and last night's announced approvals out of Decatur assuaged concerns around facility risk. In other words, two major concerns around this stock have now been removed. We have updated our model and our 2017-19E EPS move roughly $0.30 lower but still show little growth at $1.61, $1.64 and $1.69 (but we think guidance is reasonable). The re-set reduced risk but pushes valuation to 9.3x our 2018E EBITDA which is not necessarily inexpensive against the limited growth in our model." (3/2/2017)

Are investors shorting Akorn?

Akorn saw a increase in short interest during the month of November. As of November 30th, there was short interest totalling 26,139,322 shares, an increase of 4.2% from the November 15th total of 25,079,879 shares. Based on an average daily volume of 2,096,750 shares, the days-to-cover ratio is currently 12.5 days. Currently, 28.1% of the company's shares are sold short.

Who are some of Akorn's key competitors?

Who are Akorn's key executives?

Akorn's management team includes the folowing people:

  • Alan D. Weinstein, Chairman of the Board (Age 74)
  • Rajat Rai, Chief Executive Officer (Age 50)
  • Duane A. Portwood, Chief Financial Officer, Executive Vice President (Age 50)
  • Bruce K Kutinsky, Chief Operating Officer (Age 51)
  • Joseph P. Bonaccorsi, Executive Vice President, General Counsel, Secretary (Age 51)
  • Jonathon Kafer, Executive Vice President - Sales and Marketing (Age 53)
  • Steven Joseph Lichter, Executive Vice President - Pharmaceutical Operations (Age 58)
  • Randall E. Pollard, Senior Vice President, Chief Accounting Officer, Corporate Controller (Age 45)
  • Brian Tambi, Director (Age 71)
  • Kenneth S. Abramowitz, Independent Director (Age 66)

Who owns Akorn stock?

Akorn's stock is owned by many different of retail and institutional investors. Top institutional investors include Magnetar Financial LLC (2.68%), JPMorgan Chase & Co. (1.66%), Allianz Asset Management GmbH (1.20%), Alpine Associates Management Inc. (0.95%), Dimensional Fund Advisors LP (0.94%) and Bank of New York Mellon Corp (0.91%). Company insiders that own Akorn stock include Alan D Weinstein, Brian Tambi, Bruce Kutinsky, Joseph Bonaccorsi, Kenneth Abramowitz and Ronald M Johnson. View Institutional Ownership Trends for Akorn.

Who sold Akorn stock? Who is selling Akorn stock?

Akorn's stock was sold by a variety of institutional investors in the last quarter, including Pentwater Capital Management LP, Oak Ridge Investments LLC, Magnetar Financial LLC, Cowen Inc., JPMorgan Chase & Co., Thornburg Investment Management Inc., Wells Fargo & Company MN and Russell Investments Group Ltd.. Company insiders that have sold Akorn company stock in the last year include Brian Tambi and Bruce Kutinsky. View Insider Buying and Selling for Akorn.

Who bought Akorn stock? Who is buying Akorn stock?

Akorn's stock was acquired by a variety of institutional investors in the last quarter, including Cheyne Capital Management UK LLP, Alpine Associates Management Inc., APG Asset Management N.V., Cornerstone Capital Management Holdings LLC., GABELLI & Co INVESTMENT ADVISERS INC., State of Wisconsin Investment Board, First Trust Advisors LP and Havens Advisors LLC. View Insider Buying and Selling for Akorn.

How do I buy Akorn stock?

Shares of Akorn can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Akorn's stock price today?

One share of Akorn stock can currently be purchased for approximately $32.20.

How big of a company is Akorn?

Akorn has a market capitalization of $4.08 billion and generates $1.12 billion in revenue each year. The company earns $184.24 million in net income (profit) each year or $0.99 on an earnings per share basis. Akorn employs 2,388 workers across the globe.

How can I contact Akorn?

Akorn's mailing address is 1925 W. FIELD COURT SUITE 300, LAKE FOREST IL, 60045. The company can be reached via phone at 847-279-6100 or via email at [email protected]


MarketBeat Community Rating for Akorn (AKRX)

Community Ranking:  2.8 out of 5 (star star)
Outperform Votes:  377 (Vote Outperform)
Underperform Votes:  294 (Vote Underperform)
Total Votes:  671
MarketBeat's community ratings are surveys of what our community members think about Akorn and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Akorn (NASDAQ:AKRX) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: HoldHoldHoldHold
Consensus Rating Score: 2.002.002.062.06
Ratings Breakdown: 2 Sell Rating(s)
10 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
2 Sell Rating(s)
11 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
2 Sell Rating(s)
12 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
2 Sell Rating(s)
12 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $31.20$31.20$31.25$31.25
Price Target Upside: 4.06% downside4.06% downside3.82% downside5.91% downside

Akorn (NASDAQ:AKRX) Consensus Price Target History

Price Target History for Akorn (NASDAQ:AKRX)

Akorn (NASDAQ:AKRX) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
10/29/2017Jefferies GroupSet Price TargetHold$34.00N/AView Rating Details
10/22/2017Piper Jaffray CompaniesSet Price TargetHold$34.00N/AView Rating Details
10/3/2017Royal Bank of CanadaReiterated RatingHold$34.00HighView Rating Details
4/25/2017GabelliReiterated RatingBuy -> HoldHighView Rating Details
4/25/2017William BlairDowngradeOutperform -> Market PerformHighView Rating Details
4/25/2017Craig HallumDowngradeBuy -> HoldHighView Rating Details
4/10/2017Deutsche BankReiterated RatingHold$24.00LowView Rating Details
3/10/2017WallachBeth CapitalBoost Price TargetHold -> Hold$22.00 -> $25.00LowView Rating Details
12/29/2016GuggenheimReiterated RatingBuy$40.00N/AView Rating Details
12/1/2016Goldman Sachs GroupInitiated CoverageSell$20.00N/AView Rating Details
11/7/2016Bank of AmericaDowngradeBuy -> Underperform$22.00N/AView Rating Details
8/5/2016J P Morgan Chase & CoSet Price TargetBuy$45.00N/AView Rating Details
8/2/2016Raymond James FinancialDowngradeOutperform -> Market PerformN/AView Rating Details
8/2/2016CitigroupDowngradeMarket Perform$33.80 -> $34.00N/AView Rating Details
5/26/2016Leerink SwannReiterated RatingHoldN/AView Rating Details
3/23/2016Susquehanna BancsharesLower Price TargetNeutral$32.00 -> $30.00N/AView Rating Details
3/22/2016S&P Equity ResearchLower Price Target$25.98 -> $21.97N/AView Rating Details
3/21/2016NomuraLower Price TargetBuy$46.00 -> $42.00N/AView Rating Details
(Data available from 12/13/2015 forward)

Earnings

Akorn (NASDAQ:AKRX) Earnings History and Estimates Chart

Earnings by Quarter for Akorn (NASDAQ:AKRX)

Akorn (NASDAQ AKRX) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
3/1/2017Q4 2016$0.57$0.58$287.91 million$283.70 millionViewListenView Earnings Details
11/3/2016Q316$0.54$0.56$267.04 million$284.00 millionViewListenView Earnings Details
8/4/2016Q216$0.55$0.58$272.99 million$280.70 millionViewListenView Earnings Details
5/16/2016Q116$0.43$0.54$264.88 million$268.35 millionViewListenView Earnings Details
2/26/2015Q414$0.46$0.49$218.87 million$227.80 millionViewListenView Earnings Details
11/6/2014Q314$0.25$0.27$155.20 million$132.70 millionViewListenView Earnings Details
8/5/2014Q214$0.18$0.23$145.16 million$150.70 millionViewListenView Earnings Details
5/6/2014Q114$0.15$0.16$91.44 million$90.60 millionViewN/AView Earnings Details
3/3/2014Q413$0.14$0.14$83.37 million$85.00 millionViewN/AView Earnings Details
8/6/2013Q2 2013$0.13$0.14$75.06 million$77.00 millionViewN/AView Earnings Details
5/7/2013Q1 2013$0.14$0.13$74.07 million$73.90 millionViewN/AView Earnings Details
2/26/2013Q4 2012$0.12$0.13$69.42 million$71.50 millionViewN/AView Earnings Details
11/6/2012Q312$0.13$0.12$69.59 million$69.60 millionViewN/AView Earnings Details
8/7/2012$0.12$0.12ViewN/AView Earnings Details
5/8/2012$0.12$0.13ViewN/AView Earnings Details
3/6/2012$0.09$0.11ViewN/AView Earnings Details
11/1/2011$0.06$0.13ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Akorn (NASDAQ:AKRX) Earnings Estimates

Current Year EPS Consensus Estimate: $0.95 EPS
Next Year EPS Consensus Estimate: $1.16 EPS

Dividends

Dividend History for Akorn (NASDAQ:AKRX)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Akorn (NASDAQ AKRX) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 28.20%
Institutional Ownership Percentage: 73.53%
Insider Trades by Quarter for Akorn (NASDAQ:AKRX)
Institutional Ownership by Quarter for Akorn (NASDAQ:AKRX)

Akorn (NASDAQ AKRX) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
11/21/2017Brian TambiDirectorSell15,100$33.35$503,585.00View SEC Filing  
8/4/2017Brian TambiDirectorSell5,165$33.37$172,356.05View SEC Filing  
8/3/2017Bruce KutinskyCOOSell40,000$33.46$1,338,400.00View SEC Filing  
8/15/2016Kenneth AbramowitzDirectorSell2,691$30.44$81,914.04View SEC Filing  
6/14/2016Joseph BonaccorsiSVPSell6,500$29.84$193,960.00View SEC Filing  
6/10/2016Kenneth AbramowitzDirectorSell14,675$30.16$442,598.00View SEC Filing  
6/9/2016Bruce KutinskyCOOSell142,000$31.12$4,419,040.00View SEC Filing  
6/7/2016Ronald M JohnsonDirectorSell7,542$31.49$237,497.58View SEC Filing  
6/6/2016Kenneth AbramowitzDirectorSell10,900$31.37$341,933.00View SEC Filing  
6/3/2016Joseph BonaccorsiSVPSell90,250$31.23$2,818,507.50View SEC Filing  
6/2/2016Alan D WeinsteinDirectorSell50,000$30.93$1,546,500.00View SEC Filing  
4/21/2015Mark M SilverbergVPSell29,000$55.00$1,595,000.00View SEC Filing  
3/10/2015John N KapoorDirectorBuy19,000$44.26$840,940.00View SEC Filing  
3/3/2015Rajat RaiCEOBuy5,000$47.70$238,500.00View SEC Filing  
2/18/2015Joseph BonaccorsiInsiderSell40,827$47.33$1,932,341.91View SEC Filing  
2/10/2015Ronald M JohnsonDirectorSell17,173$46.44$797,514.12View SEC Filing  
1/26/2015Rajat RaiCEOSell873,985$41.89$36,611,231.65View SEC Filing  
1/12/2015Mark M SilverbergVPSell38,602$41.00$1,582,682.00View SEC Filing  
1/9/2015Ronald M JohnsonDirectorSell17,173$40.46$694,819.58View SEC Filing  
1/2/2015Ronald M JohnsonDirectorSell14,300$36.12$516,516.00View SEC Filing  
1/2/2015Timothy A DickCFOSell30,150$36.03$1,086,304.50View SEC Filing  
12/15/2014Brian TambiDirectorSell1,200$41.86$50,232.00View SEC Filing  
12/12/2014Adrienne L GravesDirectorSell9,557$41.09$392,697.13View SEC Filing  
12/11/2014John N KapoorDirectorSell50,000$41.19$2,059,500.00View SEC Filing  
12/9/2014John R SabatVPSell43,173$40.53$1,749,801.69View SEC Filing  
12/1/2014Timothy A DickCFOSell30,875$39.23$1,211,226.25View SEC Filing  
11/3/2014Timothy A DickCFOSell122,222$44.08$5,387,545.76View SEC Filing  
10/1/2014Timothy A DickCFOSell122,222$35.24$4,307,103.28View SEC Filing  
9/12/2014Brian TambiDirectorSell13,800$38.00$524,400.00View SEC Filing  
9/11/2014Joseph BonaccorsiInsiderSell116,800$37.89$4,425,552.00View SEC Filing  
9/8/2014Kenneth AbramowitzDirectorSell4,500$36.54$164,430.00View SEC Filing  
9/8/2014Rajat RaiCEOSell147,000$36.78$5,406,660.00View SEC Filing  
9/8/2014Timothy A DickCFOSell45,000$37.61$1,692,450.00View SEC Filing  
9/4/2014Alan D WeinsteinDirectorSell5,000$38.49$192,450.00View SEC Filing  
8/26/2014John N KapoorDirectorSell50,000$38.99$1,949,500.00View SEC Filing  
8/7/2014Rajat RaiCEOSell903,659$33.62$30,381,015.58View SEC Filing  
6/13/2014Brian TambiDirectorBuy1,000$27.62$27,620.00View SEC Filing  
5/16/2014Rajat RaiCEOBuy5,000$26.76$133,800.00View SEC Filing  
5/14/2014Kenneth AbramowitzDirectorSell2,557$26.79$68,502.03View SEC Filing  
12/9/2013Alan WeinsteinDirectorSell20,000$25.52$510,400.00View SEC Filing  
12/3/2013Kenneth AbramowitzDirectorSell5,000$25.35$126,750.00View SEC Filing  
12/12/2012Alan D WeinsteinDirectorBuy30,500$13.67$416,935.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Akorn (NASDAQ AKRX) News Headlines

Source:
DateHeadline
ETFs with exposure to Akorn, Inc. : December 1, 2017ETFs with exposure to Akorn, Inc. : December 1, 2017
finance.yahoo.com - December 1 at 11:18 AM
Akorn, Inc. (AKRX) Director Brian Tambi Sells 15,100 SharesAkorn, Inc. (AKRX) Director Brian Tambi Sells 15,100 Shares
www.americanbankingnews.com - November 22 at 7:57 PM
Akorn, Inc. breached its 50 day moving average in a Bearish Manner : AKRX-US : November 22, 2017Akorn, Inc. breached its 50 day moving average in a Bearish Manner : AKRX-US : November 22, 2017
finance.yahoo.com - November 22 at 4:18 PM
Analyzing Akorn (AKRX) and Its CompetitorsAnalyzing Akorn (AKRX) and Its Competitors
www.americanbankingnews.com - November 21 at 7:34 PM
Akorn, Inc. (AKRX) Receives Consensus Rating of "Hold" from BrokeragesAkorn, Inc. (AKRX) Receives Consensus Rating of "Hold" from Brokerages
www.americanbankingnews.com - November 20 at 1:52 AM
Merck & (MRK) vs. Akorn (AKRX) Financial SurveyMerck & (MRK) vs. Akorn (AKRX) Financial Survey
www.americanbankingnews.com - November 19 at 9:26 PM
ETFs with exposure to Akorn, Inc. : November 17, 2017ETFs with exposure to Akorn, Inc. : November 17, 2017
finance.yahoo.com - November 17 at 2:57 PM
Analyzing Akorn (AKRX) & Its RivalsAnalyzing Akorn (AKRX) & Its Rivals
www.americanbankingnews.com - November 13 at 3:34 AM
Breakfast Technical Briefing on Generic Drugs Stocks -- Mallinckrodt, Akorn ...Breakfast Technical Briefing on Generic Drugs Stocks -- Mallinckrodt, Akorn ...
www.prnewswire.com - November 11 at 8:55 AM
Short Interest in Akorn, Inc. (AKRX) Increases By 14.2%Short Interest in Akorn, Inc. (AKRX) Increases By 14.2%
www.americanbankingnews.com - November 11 at 3:40 AM
Breakfast Technical Briefing on Generic Drugs Stocks -- Mallinckrodt, Akorn, Pacira Pharma, and Rigel PharmaBreakfast Technical Briefing on Generic Drugs Stocks -- Mallinckrodt, Akorn, Pacira Pharma, and Rigel Pharma
www.bizjournals.com - November 10 at 7:32 PM
ETFs with exposure to Akorn, Inc. : November 6, 2017ETFs with exposure to Akorn, Inc. : November 6, 2017
finance.yahoo.com - November 6 at 4:28 PM
Financial Review: Akorn (AKRX) and Its PeersFinancial Review: Akorn (AKRX) and Its Peers
www.americanbankingnews.com - November 5 at 1:10 AM
Traders Buy High Volume of Akorn Call Options (AKRX)Traders Buy High Volume of Akorn Call Options (AKRX)
www.americanbankingnews.com - November 4 at 1:58 AM
Akorn, Inc. :AKRX-US: Earnings Analysis: Q3, 2017 By the Numbers : November 3, 2017Akorn, Inc. :AKRX-US: Earnings Analysis: Q3, 2017 By the Numbers : November 3, 2017
finance.yahoo.com - November 3 at 3:39 PM
Reviewing Akorn (AKRX) and The CompetitionReviewing Akorn (AKRX) and The Competition
www.americanbankingnews.com - November 3 at 3:18 AM
Akorn/Fresenius: Risky Arb - Seeking AlphaAkorn/Fresenius: Risky Arb - Seeking Alpha
seekingalpha.com - November 2 at 4:04 PM
Fresenius says Akorn troubles could continue into next yearFresenius says Akorn troubles could continue into next year
finance.yahoo.com - November 2 at 4:04 PM
Akorn (AKRX) Chairman John Kapoor Resigns; Alan Weinstein to Assume Role - StreetInsider.comAkorn (AKRX) Chairman John Kapoor Resigns; Alan Weinstein to Assume Role - StreetInsider.com
www.streetinsider.com - November 1 at 3:08 AM
The U.S. Has A Fentanyl Shortage...In The Clinic, Not On The StreetsThe U.S. Has A Fentanyl Shortage...In The Clinic, Not On The Streets
finance.yahoo.com - October 31 at 10:06 PM
Insys founder Kapoor steps down as Akorn chairman after arrestInsys founder Kapoor steps down as Akorn chairman after arrest
finance.yahoo.com - October 31 at 5:03 PM
Comparing Akorn (AKRX) and Johnson & Johnson (JNJ)Comparing Akorn (AKRX) and Johnson & Johnson (JNJ)
www.americanbankingnews.com - October 28 at 9:12 PM
Akorn, Inc. breached its 50 day moving average in a Bearish Manner : AKRX-US : October 27, 2017Akorn, Inc. breached its 50 day moving average in a Bearish Manner : AKRX-US : October 27, 2017
finance.yahoo.com - October 27 at 5:53 PM
John Kapoor, Founder Of Insys, Indicted On Charges Of Bribing Doctors To Overprescribe OpioidsJohn Kapoor, Founder Of Insys, Indicted On Charges Of Bribing Doctors To Overprescribe Opioids
www.msn.com - October 26 at 3:44 PM
Pre-Market Most Active for Oct 26, 2017 : NOK, MTU, TWTR, NMR, VIPS, RING, CELG, ABY, NVS, LSXMK, AKRX, QQQ - NasdaqPre-Market Most Active for Oct 26, 2017 : NOK, MTU, TWTR, NMR, VIPS, RING, CELG, ABY, NVS, LSXMK, AKRX, QQQ - Nasdaq
www.nasdaq.com - October 26 at 11:08 AM
Akorn, Inc. (AKRX) Given Average Rating of "Hold" by AnalystsAkorn, Inc. (AKRX) Given Average Rating of "Hold" by Analysts
www.americanbankingnews.com - October 26 at 1:34 AM
Short Interest in Akorn, Inc. (AKRX) Rises By 19.9%Short Interest in Akorn, Inc. (AKRX) Rises By 19.9%
www.americanbankingnews.com - October 26 at 1:20 AM
ETFs with exposure to Akorn, Inc. : October 25, 2017ETFs with exposure to Akorn, Inc. : October 25, 2017
finance.yahoo.com - October 25 at 4:35 PM
Akorn, Inc. (AKRX) Raised to "Hold" at Zacks Investment ResearchAkorn, Inc. (AKRX) Raised to "Hold" at Zacks Investment Research
www.americanbankingnews.com - October 24 at 8:38 PM
Akorn, Inc. (AKRX) Receives Hold Rating from Piper Jaffray CompaniesAkorn, Inc. (AKRX) Receives Hold Rating from Piper Jaffray Companies
www.americanbankingnews.com - October 22 at 6:58 AM
Akorn, Inc. – Value Analysis (NASDAQ:AKRX) : October 16, 2017Akorn, Inc. – Value Analysis (NASDAQ:AKRX) : October 16, 2017
finance.yahoo.com - October 16 at 4:34 PM
Akorn, Inc. breached its 50 day moving average in a Bullish Manner : AKRX-US : October 13, 2017Akorn, Inc. breached its 50 day moving average in a Bullish Manner : AKRX-US : October 13, 2017
finance.yahoo.com - October 13 at 3:38 PM
$236.10 Million in Sales Expected for Akorn, Inc. (AKRX) This Quarter$236.10 Million in Sales Expected for Akorn, Inc. (AKRX) This Quarter
www.americanbankingnews.com - October 7 at 1:50 PM
$0.24 Earnings Per Share Expected for Akorn, Inc. (AKRX) This Quarter$0.24 Earnings Per Share Expected for Akorn, Inc. (AKRX) This Quarter
www.americanbankingnews.com - October 5 at 4:28 AM
ETFs with exposure to Akorn, Inc. : September 29, 2017ETFs with exposure to Akorn, Inc. : September 29, 2017
finance.yahoo.com - October 2 at 3:34 PM
Mylan: Time To Sell?Mylan: Time To Sell?
seekingalpha.com - September 19 at 3:43 PM
Akorn, Inc. (AKRX) Sees Significant Increase in Short InterestAkorn, Inc. (AKRX) Sees Significant Increase in Short Interest
www.americanbankingnews.com - September 14 at 1:54 AM
Akorn, Inc. (Nasdaq: AKRX) to Ring The Nasdaq Stock Market Opening Bell - GlobeNewswire (press release)Akorn, Inc. (Nasdaq: AKRX) to Ring The Nasdaq Stock Market Opening Bell - GlobeNewswire (press release)
globenewswire.com - September 7 at 8:44 PM
Akorn, Inc. (Nasdaq: AKRX) to Ring The Nasdaq Stock Market Opening BellAkorn, Inc. (Nasdaq: AKRX) to Ring The Nasdaq Stock Market Opening Bell
finance.yahoo.com - September 7 at 8:44 PM
ETFs with exposure to Akorn, Inc. : August 28, 2017ETFs with exposure to Akorn, Inc. : August 28, 2017
finance.yahoo.com - August 28 at 8:52 PM
Akorn, Inc. (AKRX) Short Interest UpdateAkorn, Inc. (AKRX) Short Interest Update
www.americanbankingnews.com - August 26 at 1:48 AM
FY2017 EPS Estimates for Akorn, Inc. (AKRX) Cut by AnalystFY2017 EPS Estimates for Akorn, Inc. (AKRX) Cut by Analyst
www.americanbankingnews.com - August 25 at 9:38 AM
Why Im Not Arbing The Fresenius / Akorn Deal - Seeking AlphaWhy I'm Not Arbing The Fresenius / Akorn Deal - Seeking Alpha
seekingalpha.com - August 20 at 3:27 PM
Akorn, Inc. (AKRX) Stock Rating Reaffirmed by Royal Bank Of CanadaAkorn, Inc. (AKRX) Stock Rating Reaffirmed by Royal Bank Of Canada
www.americanbankingnews.com - August 20 at 11:26 AM
Akorn Enters Oversold Territory (AKRX)Akorn Enters Oversold Territory (AKRX)
www.nasdaq.com - August 17 at 5:08 PM
ETFs with exposure to Akorn, Inc. : August 15, 2017ETFs with exposure to Akorn, Inc. : August 15, 2017
finance.yahoo.com - August 15 at 4:46 PM
See what the IHS Markit Score report has to say about Akorn Inc.See what the IHS Markit Score report has to say about Akorn Inc.
finance.yahoo.com - August 12 at 3:31 PM
 Brokerages Expect Akorn, Inc. (AKRX) Will Post Quarterly Sales of $252.74 Million Brokerages Expect Akorn, Inc. (AKRX) Will Post Quarterly Sales of $252.74 Million
www.americanbankingnews.com - August 12 at 2:04 PM
IHS Markit Score downgrades Akorn Inc to 21 out of 100, ranking positively in only one out of three available IHS Markit categories.IHS Markit Score downgrades Akorn Inc to 21 out of 100, ranking positively in only one out of three available IHS Markit categories.
finance.yahoo.com - August 12 at 2:20 AM
Akorn, Inc. (NASDAQ:AKRX) Receives Average Recommendation of "Hold" from AnalystsAkorn, Inc. (NASDAQ:AKRX) Receives Average Recommendation of "Hold" from Analysts
www.americanbankingnews.com - August 12 at 12:44 AM

SEC Filings

Akorn (NASDAQ:AKRX) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Akorn (NASDAQ:AKRX) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Akorn (NASDAQ AKRX) Stock Chart for Wednesday, December, 13, 2017

Loading chart…

This page was last updated on 12/13/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.